Skip to main content
. 2017 Jul 19;8(35):58847–58864. doi: 10.18632/oncotarget.19375

Figure 2. CIP2A overexpression renders SKBR3 and 78617 breast cancer cells resistant to lapatinib.

Figure 2

(A) Relative CIP2A levels in stable SKBR3 and 78617 sublines transfected with control (–) or CIP2A-encoding (+) lentiviral vectors were detected with Western blotting. Survival fractions in control and CIP2A-overexpressing SKBR3 (B) and 78617 (C) cells treated with lapatinib for 5 days were measured with an MTS assay. Control and CIP2A-overexpressing SKBR3 and 78617 cells were treated with 0.3 μM lapatinib for 24 hours, followed by an apoptosis ELISA assay (D) and Western blot analysis of PARP and cleaved PARP (c-PARP) protein expression (E). All values are presented as the mean ± S.E. (**p < 0.01).